check_circleStudy Completed
Wound Healing
Bayer Identifier:
12631
ClinicalTrials.gov Identifier:
EudraCT Number:
EU CT Number:
Not Available
Pilot study to assess number of patients for main trial
Trial purpose
The objective of the study was to investigate the efficacy of Bepanthen® wound healing ointment compared to placebo in a superficial abrasive wound model. The primary objective was the re-epithelization at Day 5.
The secondary objectives were re-epithelization at Days 2, 3, 4, 6, 7, 8, 9, 10 and 15, assessment of cosmetic outcome/acceptance at Day 15 (investigator only) and at Day 36 (investigator and subject), and documentation and analysis of safety parameters.
The secondary objectives were re-epithelization at Days 2, 3, 4, 6, 7, 8, 9, 10 and 15, assessment of cosmetic outcome/acceptance at Day 15 (investigator only) and at Day 36 (investigator and subject), and documentation and analysis of safety parameters.
Key Participants Requirements
Sex
BothAge
18 - 45 YearsTrial summary
Enrollment Goal
28Trial Dates
March 2007 - April 2007Phase
Phase 4Could I Receive a placebo
YesProducts
Dexpanthenol (BAY81-2996)Accepts Healthy Volunteer
YesWhere to participate
Status | Institution | Location |
---|---|---|
Completed | proDerm | Hamburg, 22869, Germany |
Primary Outcome
- Wound healing effect (=re-epithelization) at Day 5 of the test product and the placeboWound healing effect (=re-epithelization) was determined on the following basis: No healing 0% Re-epithelization >0 up to 25% Re-epithelization >25 up to 50% Re-epithelization >50 up to 75% Re-epithelization >75 but not complete Complete closure of surface 100%date_rangeTime Frame:At Day 5enhanced_encryptionNoSafety Issue:
Secondary Outcome
- Subjective assessment of cosmetic outcomeIt was assessed by using a visual analog scale (VAS) ranging from 0 being poor, 5 being moderate to 10 being excellentdate_rangeTime Frame:At Days 15 and 36enhanced_encryptionNoSafety Issue:
- Number of participants with adverse eventsdate_rangeTime Frame:Approximately 5 weeks per subjectenhanced_encryptionYesSafety Issue:
- Wound healing at Days 2, 3, 4, 6, 7, 8, 9, 10 and 15 after wound inductiondate_rangeTime Frame:At Days 2, 3, 4, 6, 7, 8, 9, 10 and 15enhanced_encryptionNoSafety Issue:
Trial design
Trial Type
InterventionalIntervention Type
DrugTrial Purpose
TreatmentAllocation
RandomizedBlinding
Double BlindAssignment
Parallel AssignmentTrial Arms
2Additional Information
Click here and search for drug information provided by the FDA.Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.Click here to find information about studies related to Bayer Healthcare products conducted in Europe.Click here to find results for studies related to Bayer Healthcare products.